TARGETING BTN2A1 MODULATES ANTI-TUMOR ACTIVITY OF VG9VD2 T CELLS

被引：0
|
作者：
Cano, Carla [1 ]
de Gassart, Aude [1 ]
Pasero, Christine [1 ]
Gabriac, Melanie [1 ]
Fullana, Marie [1 ]
Granarolo, Emilie [1 ]
Hoet Rene [1 ]
Imbert, Caroline [1 ]
Gorvel, Laurent [2 ]
Briantais, Antoine [2 ]
Le Floch, Anne-Charlotte [2 ]
Olive, Daniel [2 ]
机构：
[1] ImCheck Therapeut, Marseille, France
[2] CRCM, Marseille, France
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0211
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
211
引用
收藏
页码：A126 / A127
页数：2
相关论文
共 50 条
  • [1] Evolution of Vg9Vd2 T cells
    Karunakaran, M. M.
    Starick, L.
    Goebel, T. W.
    Herrmann, T.
    IMMUNOLOGY, 2012, 137 : 399 - 399
  • [2] BTN2A, a New Immune-Checkpoint Targeting Vg9Vd2 T Cell Cytotoxicity
    Cano, Carla E.
    Pasero, Christine
    De Gassart, Aude
    Hoet, Rene
    Scotet, Emmanuel
    Mortier, Erwan
    Quemeneur, Agnes
    Rafia, Chirine
    Briantais, Antoine
    Le Floch, Anne-Charlotte
    Olive, Daniel
    BLOOD, 2019, 134
  • [3] Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cells
    Paniagua-Herranz, Lucia
    Diaz-Tejeiro, Cristina
    Sanvicente, Adrian
    Bartolome, Jorge
    Nieto-Jimenez, Cristina
    Ocana, Alberto
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [4] Generation and application of TGFb-educated human Vg9Vd2 T cells
    Parente-Pereira, Ana C.
    Beatson, Richard E.
    Davies, David M.
    Hull, Caroline
    Whilding, Lynsey M.
    Porter, Joanna C.
    Maher, John
    STAR PROTOCOLS, 2022, 3 (02):
  • [5] BSI-093, a best-in-class anti-BTN3A monoclonal antibody for cancer immunotherapy by activation of Vg9Vd2 T cells
    Dai, Wenwen
    Li, Jun
    Liu, Jinyu
    Li, Hongyan
    Liu, Xiaodong F.
    Xia, Shukai
    Lyu, Qun
    Davis, Hugh M.
    Chen, Mingjiu
    Peng, Zeyu
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Immunotherapy of acute myeloid leukemia using Vg9Vd2 T-cells
    Parente-Pereira, Ana C.
    Whilding, Lynsey M.
    Krishnamurthy, Pramila
    Beatson, Richard
    Zabinski, Tomasz
    Barber, Linda
    Farzaneh, Farzin
    Mufti, Ghulam
    Maher, John
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [7] ICT01, AN ANTI-BTN3A MAB THAT ACTIVATES VG9VD2 T CELLS, PLUS INTERLEUKIN-2: A POTENT AND PROMISING COMBINATION FOR CANCER IMMUNOTHERAPY
    de Gassart, Aude
    Brune, Patrick
    Suong, L. E.
    Agaugue, Sophie
    Valentin, Emmanuel
    Sims, Jennifer
    Olive, Daniel
    Frohna, Paul
    Hoet, Rene
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A268 - A269
  • [8] IL-18 Reconstitutes Vg9Vd2 T Cells in HIV plus Patient Samples
    Murday, Alanna
    Pauza, C. David
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 : 93 - 93
  • [9] BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells
    Cano, Carla E.
    Pasero, Christine
    De Gassart, Aude
    Kerneur, Clement
    Gabriac, Melanie
    Fullana, Marie
    Granarolo, Emilie
    Hoet, Rene
    Scotet, Emmanuel
    Rafia, Chirine
    Hermman, Thomas
    Imbert, Caroline
    Gorvel, Laurent
    Vey, Norbert
    Briantais, Antoine
    le Floch, Anne Charlotte
    Olive, Daniel
    CELL REPORTS, 2021, 36 (02):
  • [10] Cutting Edge: Bispecific gd T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vg9Vd2+T Cells in the Presence of Costimulation by CD28 or NKG2D
    Lai, Anne Y.
    Patel, Arpita
    Brewer, Faraha
    Evans, Kinsley
    Johannes, Kellsey
    Gonzalez, Louis E.
    Yoo, Kyung Jin
    Fromm, George
    Wilson, Keith
    Schreiber, Taylor H.
    de Silva, Suresh
    JOURNAL OF IMMUNOLOGY, 2022, 209 (08): : 1475 - 1480
12345